Impairment of ubiquitin-proteasome system activity involving ubiquitin
ligase genes UBE3A, UBE3B, and
HUWE1 and deubiquitinating enzyme genes
USP7 and USP9X has been reported in
patients with neurodevelopmental delays. To date, only handful of single
nucleotide variants (SNVs) and copy-number variants (CNVs) involving
TRIP12, encoding a member of the HECT domain E3 ubiquitin
ligases family on chromosome 2q36.3 have been reported. Using chromosomal
microarray analysis (CMA) and whole exome sequencing (WES), we have identified,
respectively, five deletion CNVs and four inactivating
SNVs (two frameshifts, one missense, and one splicing) in
TRIP12. Seven of these variants were found to be de
novo; parental studies could not be completed in two families.
Quantitative PCR analyses of the splicing mutation showed a dramatically
decreased level of TRIP12 mRNA in the proband compared to the
family controls, indicating a loss-of-function (LoF) mechanism. The shared
clinical features include intellectual disability with or without autistic
spectrum disorders, speech delay, and facial dysmorphism. Our findings
demonstrate that E3 ubiquitin ligase TRIP12 plays an important role in nervous
system development and function. The nine presented pathogenic variants further
document that TRIP12 haploinsufficiency causes childhood-onset
neurodevelopmental disorder. Finally, our data enable expansion of the
phenotypic spectrum of ubiquitin-proteasome dependent disorders.